ArticleFrontiers in immunology2026
The predictive value of modified-Naples prognostic score for patients with locally advanced non-small cell lung cancer undergoing surgery after neoadjuvant chemotherapy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the prognostic significance of the modified Naples Prognostic Score (mNPS) in patients with locally advanced non-small cell lung cancer (NSCLC) after neoadjuvant chemotherapy and surgery. Methods: We conducted 126 patients with locally advanced NSCLC who were surgically treated at the Affiliated Hospital of Shandong Second Medical University from September 2012 to April 2019. According to the albumin, cholesterol, neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR) before neoadjuvant chemotherapy, mNPS was divided into separate Groups: Group 0, Group 1, and Group 2. The Kaplan-Meier method was used to analyze survival curves according to mNPS. Univariate and multivariate Cox analyses of overall survival (OS) and progression-free survival (PFS) were then conducted. Results: Based on the mNPS system, the three Groups were defined as follows: Group 0, 20(15.9%) patients; Group 1, 85(67.5%) patients; and Group 2, 21(16.7%) patients. MNPS had a higher predictive value for OS (AUC = 0.640, P = 0.007) and PFS (AUC = 0.623, P = 0.024). Univariate analysis showed that clinical stage (P = 0.004), KPS score (P = 0.003), and surgical method (P = 0.042) were significantly correlated with OS. Clinical stage (P = 0.005), KPS score (P = 0.002), and mNPS (Group 2 vs Group 0, P = 0.002; Group 1 vs Group 0, P = 0.010) were significantly associated with PFS. Based on the positive results of univariate analyses, we performed multivariate analysis. Multivariate Cox Regression showed that clinical stage (P = 0.022), KPS score (P = 0.017), and mNPS (Group 2 vs Group 0, P = 0.008; Group 1 vs Group 0, P = 0.038) were independent prognostic factors for PFS. Conclusion: MNPS was an independent prognostic factor for PFS in patients with locally advanced non-small cell lung cancer undergoing surgery after neoadjuvant chemotherapy, but it was not an independent prognostic factor for OS. Comparatively, NPS had a higher significance in predicting the prognosis of resected locally advanced NSCLC patients receiving neoadjuvant chemotherapy and surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.